fda glp-1 warning letters november 2025 warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain FDA sends warning letter after

At Set Point Medical Weight Loss Clinic, our non-surgical medical weight loss program includes: Medical Examination and Assessment: Our team of healthcare professionals, including dietitians and exercise physiologists, conduct a thorough medical history and physical examination

Due to this shortage, pharmaceutical manufacturers have created compounded versions of Ozempic and Wegovy

For patients with obesity the population GLP-1s are prescribed to relative muscle mass and the strength-to-weight ratio may matter more than the absolute numbers that drive the Batsis benchmark

However, some patients experience persistent nausea, vomiting, or constipation and benefit from extended intervals between dose increases5 or 6 weeks rather than 4

FDA approval is a minimum standard, not a shield